Cancer Vaccine Efforts Get Boost
In May, the chancellors of The University of Texas and Texas A&M Systems signed an agreement to combine resources in creating the National Center for Therapeutic Manufacturing (NCTM), a state-of-the-art biological pharmaceutical manufacturing facility, being constructed on the A&M campus.
Through this agreement, MD Anderson will become a long-term partner and collaborator of the NCTM, increasing the ability of researchers from its laboratories to quickly provide important new cancer vaccines and treatments, including vaccines targeted to specific people.
“More than 30 potential new drugs devised at MD Anderson are in clinical trials or poised to enter clinical trials, and using this new facility will improve our drug-making efficiency tremendously, as well as lower the cost,” says Provost and Executive Vice President Raymond DuBois, M.D., Ph.D.
